We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRX
2401
DELISTED
Akorn Inc
AKRX
| $463K | ﹤0.01% |
308,822
+19,868
| +7% | +$75K |
|
2402
Greenlight Captial
GLRE
$522M
| $459K | ﹤0.01% |
45,381
+193
| +0.4% | +$2K |
|
|
AHT
2403
Ashford Hospitality Trust
AHT
$21M
| $457K | ﹤0.01% |
164
+3
| +2% | +$8.4K |
|
2404
Southern Missouri Bancorp
SMBC
$868M
| $457K | ﹤0.01% |
11,913
-27
| -0.2% | -$999 |
|
2405
Green Brick Partners
GRBK
$3.15B
| $456K | ﹤0.01% |
39,736
+98
| +0.2% | +$1.07K |
|
2406
Limoneira
LMNR
$249M
| $454K | ﹤0.01% |
23,595
+917
| +4% | +$17.5K |
|
2407
PAR Technology
PAR
$727M
| $454K | ﹤0.01% |
14,756
+128
| +0.9% | +$3.5K |
|
2408
KLX Energy Services
KLXE
$42.1M
| $453K | ﹤0.01% |
14,054
+183
| +1% | +$6.8K |
|
2409
Lindblad Expeditions
LIND
$2.24B
| $453K | ﹤0.01% |
27,676
+177
| +0.6% | +$2.83K |
|
|
GNMK
2410
DELISTED
GenMark Diagnostics, Inc
GNMK
| $453K | ﹤0.01% |
94,271
+1,372
| +1% | +$7.57K |
|
2411
Titan Machinery
TITN
$458M
| $452K | ﹤0.01% |
30,600
+264
| +0.9% | +$4.11K |
|
2412
Ardmore Shipping
ASC
$671M
| $451K | ﹤0.01% |
49,786
+61
| +0.1% | +$508 |
|
2413
Atlanta Braves Holdings Series A
BATRA
$3.39B
| $451K | ﹤0.01% |
15,224
-57
| -0.4% | -$1.63K |
|
2414
Business First Bancshares
BFST
$1.04B
| $450K | ﹤0.01% |
18,067
+81
| +0.5% | +$1.99K |
|
2415
Simulations Plus
SLP
$371M
| $450K | ﹤0.01% |
15,463
+32
| +0.2% | +$1.08K |
|
2416
Allient
ALNT
$1.58B
| $447K | ﹤0.01% |
13,815
+43
| +0.3% | +$1.2K |
|
|
CTO
2417
CTO Realty Growth
CTO
$817M
| $444K | ﹤0.01% |
27,140
+214
| +0.8% | +$3.69K |
|
2418
Citi Trends
CTRN
$606M
| $443K | ﹤0.01% |
19,152
-181
| -0.9% | -$3.53K |
|
2419
SmartFinancial
SMBK
$906M
| $443K | ﹤0.01% |
18,734
+173
| +0.9% | +$3.81K |
|
|
TECX
2420
Tectonic Therapeutic
TECX
$558M
| $442K | ﹤0.01% |
1,831
+90
| +5% | +$17.4K |
|
2421
Corbus Pharmaceuticals
CRBP
$177M
| $441K | ﹤0.01% |
2,695
+80
| +3% | +$11.8K |
|
|
STXB
2422
DELISTED
Spirit of Texas Bancshares, Inc. Common Stock
STXB
| $440K | ﹤0.01% |
19,144
+1,394
| +8% | +$30.7K |
|
2423
i3 Verticals
IIIV
$439M
| $435K | ﹤0.01% |
15,405
+114
| +0.7% | +$2.69K |
|
|
BSTC
2424
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $435K | ﹤0.01% |
7,634
+59
| +0.8% | +$3.13K |
|
|
NGM
2425
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $434K | ﹤0.01% |
+23,456
| New | +$343K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.